Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Antofagasta

(Sharecast News) - Analysts at Berenberg raised their target price on Chilean multinational Antofagasta from 2,100p to 2,200p on Friday following the group's first-half results a day earlier. Berenberg said Antofagasta's interim results were broadly in line with its expectations, but noted it also included a beat on net debt. Revenues of $3.8bn and underlying earnings of $2.2bn were both in line with estimates, while underlying earnings per share came in at $0.47, versus its $0.48 estimate.

The German bank highlighted that the beat on net debt, which at $2.3bn was well below its $2.9bn estimate, was driven by capex phasing for ongoing growth projects at Centinela and Los Pelambres, although capex was expected to rise in H2.

"Overall, this was an unsurprising set of results, with the stock closing down by c0.7% on a down day for copper prices," said Berenberg, which reiterated its 'buy' rating on the stock.

"We update our model for the H1 financial results and make slight adjustments to our estimates (ie capex phasing). This has a small impact on our estimates and our price target lifts to 2,200p per share. For investors looking for high-quality copper exposure, we think that Antofagasta is a clear stand-out. The shares are currently trading on 2.09x NAV and 7.4x 2025E EBITDA."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.